Gleevec 400 mg

Gleevec 400 mg tablets contain imatinib mesylate, a medication used to treat certain types of cancer. This oral tablet is manufactured by Novartis Pharmaceuticals Canada Inc. and is available in a pack size of 30.

Gleevec 400 mg tablets are primarily used in the treatment of specific types of cancer, including chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GIST). Imatinib mesylate, the active ingredient, works by targeting certain proteins involved in the growth of cancer cells. This medication is often prescribed as part of a broader treatment plan determined by healthcare professionals.

Common effects of Gleevec 400 mg tablets may include nausea, vomiting, diarrhea, and muscle cramps. Some individuals might experience swelling, fatigue, or skin rashes. These effects can vary in intensity and duration, and it's important to consult a healthcare provider if they become severe or persistent.

Gleevec 400 mg tablets should be handled with care, following the instructions provided by a healthcare professional. It is important to inform your healthcare provider about any other medications you are taking, as well as any pre-existing medical conditions. Regular monitoring may be required to ensure the safe and effective use of this medication.

Gleevec 400 mg tablets may interact with certain medications, including those that affect liver enzymes, such as CYP3A4 inhibitors and inducers. It is also advisable to avoid grapefruit and grapefruit juice, as they can affect the metabolism of imatinib mesylate. Always consult a healthcare provider before starting or stopping any medication while taking Gleevec.